Danielle E. Mor

This study shows that Levilactobacillus brevis, a human gut microbiome species, reduces reproductive fitness in C. elegans by impairing serotonin signaling in HSN neurons.

This study uses C. elegans to show that α-synuclein pre-formed fibrils induce prion-like aggregation and neurotoxicity, with protective effects from targeting heparan sulfate proteoglycan biosynthesis.

The paper introduces GAIT-GM, a Galaxy tool for multi-omics analysis, and finds a link between branched-chain amino acid metabolism and cholinergic neuron defects in a C. elegans Parkinson's disease model.

The paper identifies four FDA-approved drugs, including metformin, as potential Parkinson's disease therapeutics using a high-throughput behavioral screen in C. elegans.

This study shows that metabolic defects in C. elegans lead to hyperactive mitochondria and Parkinson's-like traits, with metformin improving motor function and reducing neurodegeneration.